GlassScriptPhysician profile
Aravind Swaminathan
NPI 1407046402
$49,389.33
in general payments reported to CMS, 2019-2025
5 companies · $5,941 in 2025
The $5,941 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $12K · 2021: $7,742 · 2023: $951 · 2024: $60.06 · 2025: $5,941.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,000 · Travel and Lodging: $2,045 · Food and Beverage: $908.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,000.00 |
| Travel and Lodging | $2,044.68 |
| Food and Beverage | $907.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotrace Medical, INC. | $42,420.00 | 2019-2021 | |
| Merit Medical Systems INC | $4,000.00 | 2025 | |
| Biotronik INC. | $1,771.86 | 2025 | Solia |
| Medtronic, INC. | $1,158.60 | 2021-2025 | Micra, Aurora Ev-Icd Mri Surescan |
| Irhythm Technologies, INC. | $38.87 | 2024 | Zio Xt Patch |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,517,843.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aravind Swaminathan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.